Immunochemotherapy with rituximab, XXXX , @entity4174 , and @entity11770 for primary CNS lymphoma ( @entity149 ) in the elderly.

@entity1 @entity4174 @entity149 @entity11770 @entity1893 @entity1499 @entity1349
BACKGROUND: @entity149 ( @entity149 ) is an aggressive extranodal @entity1893 confined to the central nervous system. In this article, we report the results of a pilot trial adding rituximab to the established regimen consisting of @entity1499 , @entity4174 , and @entity11770 (R-MCP). DESIGN AND METHODS: @entity149 @entity1 >= 65 years without Karnofsky performance score (KPS) limit were included. R-MCP regimen consisted of rituximab (375 mg/m(2) i.v. on days -6, 1, 15, and 29), @entity1499 (3 g/m(2) i.v., days 2, 16, and 30) followed by folinic rescue, @entity4174 (60 mg/m(2) orally, days 2-11), and @entity11770 (110 mg/m(2) orally, day 2). A maximum of three 43-day cycles were applied. Primary end point was response to treatment obtained by magnetic resonance imaging. Secondary end points were @entity1349 ( @entity1349 ) and progression-free survival (PFS). RESULTS: Twenty-eight @entity1 were included (median age 75, median KPS 60%). Best documented response: complete remission in 18 of 28 (64%), partial remission in 5 of 28 (18%), stable disease in 1 of 28 (4%), and progressive disease in 2 of 28 (7%) @entity1 . Response was not assessed in two @entity1 . Two treatment-associated deaths were observed. After a median follow-up of 36 months, the 3-year PFS and @entity1349 was 31%. CONCLUSION: R-MCP regimen is well tolerated and active in elderly @entity1 with newly diagnosed @entity149 .
